Harmony Biosciences (NASDAQ:HRMY) Issues Earnings Results

08 May 2026, 18:00 by Scott Moore · The Cerbat Gem

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21), FiscalAI reports. Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The business had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. During the same quarter last year, the firm earned $0.78 EPS. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year.

Here are the key takeaways from Harmony Biosciences’ conference call:

Harmony reported $215.4 million in Q1 net product revenue (up 17% YoY), about 8,500 average patients (8,600 exit), and reiterated full‑year revenue guidance of $1.0B–$1.04B.
The company is defending a multi‑layered pitolisant IP estate after settling with 6 of 7 ANDA filers (LOE into March 2030) but faces ongoing ANDA litigation and a newly filed amorphous patent suit vs AET/Sandoz, creating legal uncertainty.
BP‑205 is presented as a potential best‑in‑class orexin‑2 agonist with compelling preclinical data and is on track for phase I single ascending‑dose PK topline data in mid‑2026 and a U.S. IND submission later in 2026.
Lifecycle programs are advancing — Pitolisant GR on track for NDA submission this quarter (PDUFA targeted Q1 2027), Pitolisant HD is enrolling two phase III trials (topline 2027), and Harmony has ~$878M cash to pursue BD opportunities targeting 2028–2032 revenues.

Harmony Biosciences Stock Performance

HRMY traded down $0.43 during trading on Friday, reaching $30.99. 750,798 shares of the company were exchanged, compared to its average volume of 879,941. Harmony Biosciences has a 52 week low of $25.52 and a 52 week high of $40.87. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average of $29.01 and a 200 day moving average of $33.04. The stock has a market cap of $1.79 billion, a P/E ratio of 11.44, a PEG ratio of 0.44 and a beta of 0.97.

Hedge Funds Weigh In On Harmony Biosciences

Institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new stake in shares of Harmony Biosciences in the 4th quarter worth about $47,000. National Bank of Canada FI bought a new position in Harmony Biosciences in the 3rd quarter worth about $40,000. PNC Financial Services Group Inc. increased its stake in shares of Harmony Biosciences by 30.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,663 shares of the company’s stock valued at $100,000 after purchasing an additional 619 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Harmony Biosciences by 338.9% in the second quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock valued at $111,000 after purchasing an additional 2,711 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Harmony Biosciences during the second quarter valued at approximately $120,000. Institutional investors own 86.23% of the company’s stock.

More Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

Positive Sentiment: Harmony Biosciences reaffirmed 2026 net revenue guidance of over $1 billion and said demand for WAKIX remained strong, which helps support the long-term outlook. Business Wire article
Positive Sentiment: H.C. Wainwright reiterated a Buy rating and a $55 price target, citing positive discussions with senior management and reinforcing bullish sentiment on the stock. InsiderMonkey article
Neutral Sentiment: Several articles noted Harmony Biosciences as a small-cap value name with a relatively low forward P/E, which may attract value investors but does not directly change the near-term earnings picture. InsiderMonkey article
Neutral Sentiment: Truist raised its price target to $29 from $25 but kept a Hold rating, suggesting only limited upside from current levels. Tickerreport article
Negative Sentiment: Q1 earnings of $0.55 per share missed estimates of $0.76, and revenue of $215.4 million also came in below expectations, which is the main reason shares are under pressure today. Zacks article
Negative Sentiment: Management said Q1 market access headwinds were more pronounced this year, which may raise investor concerns about near-term execution even with strong year-over-year revenue growth. Business Wire article

Analysts Set New Price Targets

HRMY has been the subject of several recent research reports. Needham & Company LLC dropped their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Truist Financial upped their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research note on Wednesday, February 25th. UBS Group decreased their price target on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price target on the stock. in a report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $40.89.

Read Our Latest Stock Analysis on HRMY

About Harmony Biosciences

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.